Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.

Are you looking for our logo? You can download our logo and get information about how to use it on our sharing page

Latest news

Exciting Experiments in "Open Science" by Huntington's Researchers

Exciting Experiments in "Open Science" by Huntington's Researchers

Anna Marie Yanny on April 20, 2018

Drs Rachel Harding and Tam Maiuri are taking a leap of faith to make discoveries in Huntington’s Disease (HD) research swift and open to all. They are publishing their lab notes on fundamental HD research online in real time, at the risk of losing credit for their work. As a result, they hope to speed the path of discovery to more effective HD treatments.

The structure of the protein that causes Huntington's disease, revealed

The structure of the protein that causes Huntington's disease, revealed

Caroline Casey on April 03, 2018

The cause of Huntington’s disease has been known since 1993, but the physical structure of the healthy huntingtin protein proved difficult to discover until now. German scientists have now revealed the shape of the huntingtin protein for the first time. Although the structure of the mutant form of the protein was not investigated, this study provides an excellent platform to build upon and will boost drug development efforts.

Huntington's disease therapeutics conference 2018 - day 3

Huntington's disease therapeutics conference 2018 - day 3

Dr Jeff Carroll on March 02, 2018

Good morning from the final day of the 2018 HD Therapeutics Conference! Two sessions today, the first focused on the protein made from the HD gene. The second includes updates on Huntingtin Lowering Trials from both Wave Life Sciences and Ionis Pharmaceuticals.

Huntington's disease therapeutics conference 2018 - day 2

Huntington's disease therapeutics conference 2018 - day 2

Dr Jeff Carroll on March 01, 2018

Updates from day 2 of the Huntington's Disease Therapeutics Conference focusing on DNA repair in HD.

Huntington's disease therapeutics conference 2018 - day 1

Huntington's disease therapeutics conference 2018 - day 1

Dr Ed Wild on February 28, 2018

Jeff and Ed report from the Huntington's Disease Therapeutics Conference - the biggest annual gathering of HD researchers. This year's conference is bigger and more exciting than ever.

An early role for the Huntington's disease gene – but don't believe all the headlines

An early role for the Huntington's disease gene – but don't believe all the headlines

Dr Jeff Carroll on February 27, 2018

New hints are emerging about the normal role of the gene that causes Huntington's disease. A recent report uses cutting edge techniques to study this question in cells growing in the lab. We'll help separate the fascinating new science from some scary-sounding headlines.

New interest in an old target

New interest in an old target

Dr Jeff Carroll on January 30, 2018

A recent mouse study of a drug known as CTEP suggests the drug is surprisingly helpful for HD-like symptoms in mice. This is a welcome surprise, because it suggests a well-understood brain process might be a useful drug target for future HD research.

Ask the expert: Q&A on the huntingtin-lowering trial program

Ask the expert: Q&A on the huntingtin-lowering trial program

Dr Ed Wild on December 18, 2017

The research news, announced on 11 December 2017, that a research team from the Huntington's Disease Centre at University College London have made significant step towards a possible treatment for Huntington's disease, raised many questions for the Huntington's disease community. Dr Ed Wild answered some of these questions on behalf of the UK HD Association, helping to give some context to what this news means for people affected by Huntington's now and in the future.

Success! ASO drug reduces levels of mutant protein in Huntington's disease patients

Success! ASO drug reduces levels of mutant protein in Huntington's disease patients

Dr Jeff Carroll on December 11, 2017

In an announcement likely to stand as one of the biggest breakthroughs in Huntington's disease since the discovery of the HD gene in 1993, Ionis and Roche today announced that the first human trial of a huntingtin-lowering drug, IONIS-HTTRx, demonstrates that it reduces mutant huntingtin in the nervous system, and is safe and well-tolerated.